Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data.
Biomarkers
Body mass index
Co-morbidities
Disease severity
Heart failure
Obesity
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
14
12
2020
accepted:
11
02
2021
pubmed:
12
3
2021
medline:
30
12
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Higher body mass index (BMI) is associated with better outcome compared with normal weight in patients with HF and other chronic diseases. It remains uncertain whether the apparent protective role of obesity relates to the absence of comorbidities. Therefore, we investigated the effect of BMI on outcome in younger patients without co-morbidities as compared to older patients with co-morbidities in a large heart failure (HF) population. In an individual patient data analysis from pooled cohorts, 5,819 patients with chronic HF and data available on BMI, co-morbidities and outcome were analysed. Patients were divided into four groups based on BMI (i.e. ≤ 18.5 kg/m Mean age was 65 ± 12 years, with a majority of males (78%), ischaemic HF and HF with reduced ejection fraction. Frequency of all-cause mortality or HF hospitalization was significantly worse in the lowest two BMI groups as compared to the other two groups; however, this effect was only seen in patients older than 75 years or having at least one relevant co-morbidity, and not in younger patients with HF only. After including medications and N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin concentrations into the model, the prognostic impact of BMI was largely absent even in the elderly group with co-morbidity. The present study suggests that obesity is a marker of less advanced disease, but does not have an independent protective effect in patients with chronic HF. Categories of BMI are only predictive of poor outcome in patients aged > 75 years or with at least one co-morbidity (bottom), but not in those aged < 75 years without co-morbidities (top). The prognostic effect largely disappears in multivariable analyses even for the former group. These findings question the protective effect of obesity in chronic heart failure (HF).
Sections du résumé
BACKGROUND
BACKGROUND
Higher body mass index (BMI) is associated with better outcome compared with normal weight in patients with HF and other chronic diseases. It remains uncertain whether the apparent protective role of obesity relates to the absence of comorbidities. Therefore, we investigated the effect of BMI on outcome in younger patients without co-morbidities as compared to older patients with co-morbidities in a large heart failure (HF) population.
METHODS
METHODS
In an individual patient data analysis from pooled cohorts, 5,819 patients with chronic HF and data available on BMI, co-morbidities and outcome were analysed. Patients were divided into four groups based on BMI (i.e. ≤ 18.5 kg/m
RESULTS
RESULTS
Mean age was 65 ± 12 years, with a majority of males (78%), ischaemic HF and HF with reduced ejection fraction. Frequency of all-cause mortality or HF hospitalization was significantly worse in the lowest two BMI groups as compared to the other two groups; however, this effect was only seen in patients older than 75 years or having at least one relevant co-morbidity, and not in younger patients with HF only. After including medications and N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin concentrations into the model, the prognostic impact of BMI was largely absent even in the elderly group with co-morbidity.
CONCLUSIONS
CONCLUSIONS
The present study suggests that obesity is a marker of less advanced disease, but does not have an independent protective effect in patients with chronic HF. Categories of BMI are only predictive of poor outcome in patients aged > 75 years or with at least one co-morbidity (bottom), but not in those aged < 75 years without co-morbidities (top). The prognostic effect largely disappears in multivariable analyses even for the former group. These findings question the protective effect of obesity in chronic heart failure (HF).
Identifiants
pubmed: 33704552
doi: 10.1007/s00392-021-01822-1
pii: 10.1007/s00392-021-01822-1
pmc: PMC8318940
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Troponin
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
1280-1291Informations de copyright
© 2021. The Author(s).
Références
J Obes. 2016;2016:9040248
pubmed: 26904277
Clin Chem Lab Med. 2018 Jun 27;56(7):1015-1025
pubmed: 29381470
J Am Coll Cardiol. 2014 Mar 4;63(8):778-85
pubmed: 24315906
Eur J Heart Fail. 2018 Nov;20(11):1580-1587
pubmed: 30160804
Circ Res. 2016 Apr 1;118(7):1151-69
pubmed: 27034277
PLoS One. 2017 Jul 13;12(7):e0181212
pubmed: 28704534
Eur J Heart Fail. 2011 Feb;13(2):130-2
pubmed: 21262928
Eur J Prev Cardiol. 2019 Nov;26(16):1751-1759
pubmed: 31154828
J Am Med Dir Assoc. 2015 Oct 1;16(10):884-91
pubmed: 26255708
Eur J Heart Fail. 2016 May;18(5):545-53
pubmed: 27135769
Clin Res Cardiol. 2019 Feb;108(2):119-132
pubmed: 29951802
Eur J Heart Fail. 2016 Jul;18(7):851-8
pubmed: 27312985
Eur J Heart Fail. 2018 Sep;20(9):1269-1277
pubmed: 29963737
Int J Obes Relat Metab Disord. 2002 Jun;26(6):789-96
pubmed: 12037649
Metabolism. 2016 May;65(5):728-735
pubmed: 27085779
Cardiovasc Diabetol. 2017 Sep 25;16(1):119
pubmed: 28946871
J Am Coll Cardiol. 2004 Apr 21;43(8):1439-44
pubmed: 15093881
Int J Cardiol. 2013 Jul 1;166(3):601-5
pubmed: 22204855
Eur J Prev Cardiol. 2021 Aug 9;28(9):948-955
pubmed: 34402870
N Engl J Med. 2007 Nov 29;357(22):2248-61
pubmed: 17984166
Heart. 2020 Jan;106(1):58-68
pubmed: 31530572
J Am Heart Assoc. 2016 Mar 24;5(3):e002468
pubmed: 27013541
Eur J Heart Fail. 2015 Oct;17(10):1006-14
pubmed: 26472682
JACC Heart Fail. 2013 Apr;1(2):93-102
pubmed: 24621833
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):151-156
pubmed: 29852198
Int J Cardiol. 2008 Jun 23;127(1):5-16
pubmed: 18191484
Int J Epidemiol. 2006 Feb;35(1):83-92
pubmed: 16339600
J Card Fail. 2010 Nov;16(11):867-72
pubmed: 21055650
Lancet. 2003 Mar 29;361(9363):1077-83
pubmed: 12672310
Heart. 2015 Oct;101(20):1631-8
pubmed: 26025084
Int J Cardiol. 2018 Jun 15;261:189-195
pubmed: 29551255
Int J Cardiol. 2014 Oct 20;176(3):611-7
pubmed: 25156856
J Clin Endocrinol Metab. 2015 Dec;100(12):4570-8
pubmed: 26469382
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Am J Cardiol. 2015 May 15;115(10):1428-34
pubmed: 25772740
Am J Cardiol. 2015 Jan 15;115(2):209-13
pubmed: 25465933
J Am Coll Cardiol. 2009 May 26;53(21):1925-32
pubmed: 19460605
Circulation. 2018 Jan 16;137(3):286-297
pubmed: 29335288
Lancet. 1999 May 29;353(9167):1838-42
pubmed: 10359409